STOCK TITAN

Anaptys Announces Participation in November Investor Conferences

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.

Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

-3.61%
3 alerts
-3.61% News Effect
+5.4% Peak Tracked
-$41M Valuation Impact
$1.10B Market Cap
0.7x Rel. Volume

On the day this news was published, ANAB declined 3.61%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $41M from the company's valuation, bringing the market cap to $1.10B at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

TD Cowen Immunology & Inflammation Summit, Virtual

  • Format – Fireside chat
  • Date and Time – Wednesday, Nov. 12, 2025 at 8:00am ET

Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA

  • Format – Fireside chat and 1x1 investor meetings
  • Date and Time – Wednesday, Nov. 12, 2025 at 11:30am ET

Stifel 2025 Healthcare Conference, New York, NY

  • Format – Fireside chat and 1x1 investor meetings
  • Date and Time – Thursday, Nov. 13, 2025 at 1:20pm ET

Jefferies Global Healthcare Conference, London, UK

  • Format – Presentation and 1x1 investor meetings
  • Date and Time – Monday, Nov. 17, 2025 at 4:00pm GMT

Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication. Additionally, ANB101, a BDCA2 modulator, is in a Phase 1a trial. Anaptys also has discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here

Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com


FAQ

When will Anaptys (ANAB) present at the TD Cowen Immunology & Inflammation Summit?

Anaptys will hold a virtual fireside chat on Nov 12, 2025 at 8:00 AM ET.

How can investors watch Anaptys (ANAB) presentations on Nov 12–17, 2025?

Live webcasts will be available on Anaptys’ investor presentations and events page, with replays for at least 30 days.

What format will Anaptys use at the Guggenheim Healthcare Innovation Conference on Nov 12, 2025?

Anaptys will participate in a fireside chat and 1x1 investor meetings on Nov 12, 2025 at 11:30 AM ET in Boston.

When is Anaptys (ANAB) scheduled at the Stifel 2025 Healthcare Conference?

Anaptys is scheduled for a fireside chat and 1x1 meetings on Nov 13, 2025 at 1:20 PM ET in New York.

What is the date and format for Anaptys at the Jefferies Global Healthcare Conference in London?

Anaptys will give a presentation and hold 1x1 meetings on Nov 17, 2025 at 4:00 PM GMT.

Will Anaptys (ANAB) make replays of the investor webcasts available and for how long?

Yes. Replays will be available on the investor site for at least 30 days after each event.
Anaptysbio Inc

NASDAQ:ANAB

ANAB Rankings

ANAB Latest News

ANAB Latest SEC Filings

ANAB Stock Data

1.33B
26.01M
5.82%
124.31%
34.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO